Y-box-binding protein 1 and epithelialmesenchymal transition

doi:10.3760/cma.j.issn.1673-422X.2013.12.005

Abstract

Abstract: In the process of epithelialmesenchymal transition (EMT), cellcell adherence is disrupted, apicobasal polarity is lost, the ability of antiapoptosis, migration and invasion is acquired. Yboxbinding protein 1 (YB1) is a member of the coldshock protein superfamily, containing a structurally and functionally conserved cold shock domain. Studies indicate that YB1 can promote the occurrence and development of tumors by regulating EMT. In the process of EMT mediated by YB1, various transcription factors and signal pathways play important roles.

Key words: Yboxbinding protein 1, Cell transformation, neoplastic, Transcription factors, Signal transduction

YAN Xue-Bing, ZHU Qing-Chao, JIN Zhi-Ming. Y-box-binding protein 1 and epithelialmesenchymal transition[J]. Journal of International Oncology, 2013, 40(12): 896-899.

References

［1］ Eliseeva IA, Kim ER, Guryanov SG, et al. Yboxbinding protein 1 (YB1) and its functions. Biochemistry (Mosc), 2011, 76(13): 14021433. ［2］ Lasham A, Samuel W, Cao H, et al. YB1, the E2F pathway, and regulation of tumor cell growth. J Natl Cancer Inst, 2012, 104(2): 133146. ［3］ Lasham A, Moloney S, Hale T, et al. The Yboxbinding protein, YB1, is a potential negative regulator of the p53 tumor suppressor. J Biol Chem, 2003, 278(37): 3551635523. ［4］ Takahashi M, Shimajiri S, Izumi H, et al. Ybox binding protein1 is a novel molecular target for tumor vessels. Cancer Sci, 2010, 101(6): 13671373. ［5］ Astanehe A, Finkbeiner MR, Hojabrpour P, et al. The transcriptional induction of PIK3CA in tumor cells is dependent on the oncoprotein Ybox binding protein1. Oncogene, 2009, 28(25): 24062418. ［6］ Schittek B, Psenner K, Sauer B, et al. The increased expression of Y boxbinding protein 1 in melanoma stimulates proliferation and tumor invasion, antagonizes apoptosis and enhances chemoresistance. Int J Cancer, 2007, 120(10): 21102118. ［7］ Onder TT, Gupta PB, Mani SA, et al. Loss of Ecadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res, 2008, 68(10): 36453654. ［8］ SánchezTilló E, Liu Y, de Barrios O, et al. EMTactivating transcription factors in cancer: beyond EMT and tumor invasiveness. Cell Mol Life Sci, 2012, 69(20): 34293456. ［9］ Kroepil F, Fluegen G, Vallbhmer D, et al. Snail1 expression in colorectal cancer and its correlation with clinical and pathological parameters. BMC Cancer, 2013, 13: 145. ［10］ Evdokimova V, Tognon C, Ng T, et al. Translational activation of snail1 and other developmentally regulated transcription factors by YB1 promotes an epithelialmesenchymal transition. Cancer Cell, 2009, 15(5): 402415. ［11］ Fu J, Qin L, He T, et al. The TWIST/Mi2/NuRD protein complex and its essential role in cancer metastasis. Cell Res, 2011, 21(2): 275289. ［12］ Yang F, Sun L, Li Q, et al. SET8 promotes epithelialmesenchymal transition and confers TWIST dual transcriptional activities. EMBO J, 2012, 31(1): 110123. ［13］ Shiota M, Yokomizo A, Itsumi M, et al. Twist1 and Yboxbinding protein1 promote malignant potential in bladder cancer cells. BJU Int, 2011, 108(2 Pt 2): E142149. ［14］ Song YH, Shiota M, Yokomizo A, et al. Twist1 and Yboxbinding protein1 are potential prognostic factors in bladder cancer. Urol Oncol, 2013, In press. ［15］ Jürchott K, Kuban RJ, Krech T, et al. Identification of Ybox binding protein 1 as a core regulator of MEK/ERK pathwaydependent gene signatures in colorectal cancer cells. PLoS Genet, 2010, 6(12): e1001231. ［16］ Toulany M, Schickfluss TA, Eicheler W, et al. Impact of oncogenic KRAS on YB1 phosphorylation induced by ionizing radiation. Breast Cancer Res, 2011, 13(2): R28. ［17］ Sinnberg T, Sauer B, Holm P, et al. MAPK and PI3K/AKT mediated YB1 activation promotes melanoma cell proliferation which is counteracted by an autoregulatory loop. Exp Dermatol, 2012, 21(4): 265270. ［18］ Lyabin DN, Eliseeva IA, Ovchinnikov LP. YB1 synthesis is regulated by mTOR signaling pathway. PLoS One, 2012, 7(12): e52527. ［19］ Rauen T, Raffetseder U, Frye BC, et al. YB1 acts as a ligand for Notch3 receptors and modulates receptor activation. J Biol Chem, 2009, 284(39): 2692826940. ［20］ Lee C, Dhillon J, Wang MY, et al. Targeting YB1 in HER2 overexpressing breast cancer cells induces apoptosis via the mTOR/STAT3 pathway and suppresses tumor growth in mice. Cancer Res, 2008, 68(21): 86618666. ［21］ Takeuchi A, Shiota M, Tatsugami K, et al. YB1 suppression induces STAT3 proteolysis and sensitizes renal cancer to interferonα. Cancer Immunol Immunother, 2013, 62(3): 517527. ［22］ Fraser DJ, Phillips AO, Zhang X, et al. Ybox protein1 controls transforming growth factorβ1 translation in proximal tubular cells. Kidney Int, 2008, 73(6): 724732. ［23］ Higashi K, Inagaki Y, Fujimori K, et al. Interferongamma interferes with transforming growth factorbeta signaling through direct interaction of YB1 with Smad3. J Biol Chem, 2003, 278(44): 4347043479. ［24］ Bader AG, Felts KA, Jiang N, et al. Y boxbinding protein 1 induces resistance to oncogenic transformation by the phosphatidylinositol 3kinase pathway. Proc Natl Acad Sci USA, 2003, 100(21): 1238412389. ［25］ Evdokimova V, Tognon C, Ng T, et al. Reduced proliferation and enhanced migration: two sides of the same coin? Molecular mechanisms of metastatic progression by YB1. Cell Cycle, 2009, 8(18): 29012906.

[1]	Zhang Dandan, Lin Gaoren, Xiao Qian, Liu Ying. Roles of the SoxC family in tumor development and its clinical significance [J]. Journal of International Oncology, 2022, 49(7): 416-419.
[2]	Du Jingquan*, Guo Xiaoling, Wei Yongli, Li Keming, Yu Hao. Network pharmacology based study on mechanism of peony leaf in the treatment of cervical cancer [J]. Journal of International Oncology, 2018, 45(8): 519-524.
[3]	Zhang Yuanyuan, Zhu Shuxia. Mechanism of microRNA-495 in glioma [J]. Journal of International Oncology, 2018, 45(6): 362-364.
[4]	ZHUANG Wen-Yuan, GAN Wei-Dong. Mechanism of microphthalmia family of transcription factors in tumorigenesis [J]. Journal of International Oncology, 2018, 45(5): 292-295.
[5]	Xing Rongchun， Qin Zhouping. Study on cell matrix of pancreatic duct adenocarcinoma [J]. Journal of International Oncology, 2018, 45(11): 696-698.
[6]	Sun Fei, Wang Jianlin, Yu Jingping. Research advances of cancer therapy targeting HIF-1α-VEGF-VEGFR-2 signaling pathway for malignant tumors [J]. Journal of International Oncology, 2017, 44(6): 456-.
[7]	Yang Feilong, Li Dawei, Ren Juchao, Yan Lei, Zhou Zunlin, Liu Hainan, Xu Zhonghua. Expression of hepatomaderived growth factor in tumor and its related signaling pathway [J]. Journal of International Oncology, 2017, 44(3): 193-195.
[8]	Wang Hao, Zhang Qingling. PI3K signaling pathway in colorectal cancer [J]. Journal of International Oncology, 2016, 43(8): 631-633.
[9]	Li Lihong, Bai Zhongtian, Hu Jinjing, Zhou Wence. Progression of secreted frizzled-related protein family in cancer [J]. Journal of International Oncology, 2016, 43(6): 448-451.
[10]	HE Hui-Ping, XU Zu-Min, GUAN Cheng-Nong. SOX7 and its expression and function in tumors [J]. Journal of International Oncology, 2016, 43(4): 271-273.
[11]	TIAN Chuan, LI Qi. Mechanisms of FOXM1 in carcinogenesis and the progression of the antiFOXM1 target drugs [J]. Journal of International Oncology, 2016, 43(4): 274-277.
[12]	LIU Tian-Tian, BI Jing-Wang. 3Phosphoinositidedependent protein kinase1 in tumor genesis, development and treatment [J]. Journal of International Oncology, 2016, 43(4): 285-288.
[13]	LIU Jing, WU Yong-Qiang, GUO Geng, WANG Xiao-Gang. Effect and mechanism of NF-κB signaling pathway on the biological characteristics of glioma [J]. Journal of International Oncology, 2016, 43(12): 924-926.
[14]	Lian Yifan, Wang Keming. Molecular mechanism of long non-coding RNAs in tumor drug resistance [J]. Journal of International Oncology, 2015, 42(6): 439-441.
[15]	Chen Qingfa, Zhao Zongjie, Xie Haitao, Zhang Xiangyang, Wang Pengting. Research progress of Antrodia cinnomomea on the anti-hepatocarcinoma mechanism [J]. Journal of International Oncology, 2015, 42(6): 469-471.